替尼泊甙加顺铂联合治疗肺癌的临床研究

CLINICAL STUDY OF TENIPOSIDE IN COMBINATION WITH CISPLATIN IN TREATMENT OF LUNG CANCER

目的：研究替尼泊甙加顺铂联合治疗肺癌患者的疗效和毒性。方法：符合肿瘤化疗规定的５２例肺癌患者纳入本组，可评估５０例，共完成１１６周期化疗。ＴＰ方案组成：ｔｅｎｉｐｏｓｉｄｅ６０ｍｇ／ｍ２，静脉滴注，ｄ１～３；ｃｉｓｐｌａｔｉｎ２５ｍｇ／ｍ２，ｉｖ，ｄ１～３，每３～４周重复。结果：有效率５６％（２８／５０），完全缓解率８％（４／５０）。其中小细胞肺癌有效率８０％（２０／２５），非小细胞肺癌有效率３２％（８／２５）（Ｐ＜０．０１）。在１０例发生脑转移的患者中，４例获得部分缓解。全组中数缓解期６个月（２～１５月），中数生存期为９个月（２～１６月）。最常见的毒副反应是白细胞减少（Ⅲ°～Ⅳ°，３８％），脱发（Ⅲ°，２０％）和恶心呕吐（Ⅲ°，６％）。结论：该方案不仅是治疗小细胞肺癌最为有效的方案之一，而且对非小细胞肺癌亦有较好疗效，尤其适用于合并脑转移患者。

OBJECTIVE:To define the activity and toxicity of teniposide in combination with cisplatin in treatment of lung cancer.METHODS:52 eligible cancer were enrolled.50 of them were evaluated after receiving 116 cycles of chemotherapy in TP regimen(teniposide 60 mg/m2 iv d13,cisplatin 25 mg/m2 iv d13,repeated every 3～4 weeks).RESULTS:The total remission rate is 56%(28/50),the complete remission rate is 8%(4/50).The remission rate of small cell lung cancer and nonsmall cell lung cancer are 80%(20/25)and 32%(8/25)(P<0.01),respectively,4 of the 10 patients with brain metastases achieved partial remission.The median duration of response was 6 months(range 2～15)and the median survival time was 9 months (range 2～16).Leukocytopenia(Ⅲ～Ⅳ°,38%),alopecia(Ⅲ°,20%),nausea and vomiting(Ⅲ°,6%)were the most common side effects.CONCLUSION:TP regimen is one of the most effective regimens for small cell lung cancer,as well as for nonsmall cell lung cancer,especially for the patients with brain metastases.